Canadian clinical-stage biopharmaceutical company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) announced on Thursday the appointment of Brittany Davison, CPA, CA as its new business advisor.
Davison, a chartered professional accountant, is the owner of Davison CPA Consulting Inc of Halifax, Nova Scotia. She previously served as chief accounting officer and acting chief financial officer at IMV Inc and as audit senior with Grant Thornton LLP.
Kenneth Kovan, BioVaxys president & chief operating officer, said: "We are delighted to have engaged Brittany who is a significant addition to our team where she will assist with further knowledge transfer associated with the former IMV Inc assets, support investor relations, business development targeting and outreach, and facilitate sources of private funding, government funding and Scientific Research and Experimental Development (SR&ED) tax incentives."
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma